Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could this daily pill slow ALS?

NCT ID NCT05740813

Completed Disease control Sponsor: Merit E. Cudkowicz, MD Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 2/3 trial tested an oral drug called ABBV-CLS-7262 in 310 people with ALS. Participants took the drug or a placebo once daily for 24 weeks. The study measured how fast the disease progressed and survival rates. The goal was to see if the drug could slow ALS and improve quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ABBV-CLS-7262 (an oral drug taken once daily)
What this could lead to
If successful, this could point toward a treatment that slows the progression of ALS and helps maintain physical function.
What could go wrong
This is an early-to-mid stage trial (Phase 2/3) with only 310 participants, so results may not confirm benefit. The drug may not slow disease or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AMYOTROPHIC LATERAL SCLEROSIS

Contacts and locations

Locations

  • Healey Center for ALS at Mass General

    Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.